MargaretBlockMD

Oncology • Omaha, NE

Breast Cancer, Hematologic Oncology

Physician

Join to view full profile

Dr. Block is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Block's full profile

Already have an account?

Office
7500 Mercy Rd
Ste 1300
Omaha, NE 68124
Phone+1 402-393-3110

Fax+1 402-393-4499

Education & Training

University of Wisconsin Hospitals and ClinicsFellowship, Medical Oncology, 1980 - 1981
Rush University Medical CenterFellowship, Hematology and Medical Oncology, 1979 - 1980
Rush University Medical CenterResidency, Internal Medicine, 1976 - 1979
Albany Medical CollegeClass of 1976

Certifications & Licensure

IA State Medical License 1989 - 2026
NE State Medical License 1989 - 2026
WI State Medical License 1980 - 2025
IL State Medical License 1977 - 1993
PA State Medical License 1983 - 1990
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer Start of enrollment: 2012 Apr 01
Terminated
Phase 2
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index Start of enrollment: 2013 Apr 01
Completed
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 22
Active, not recruiting
Phase 3
A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib Start of enrollment: 2017 Jun 07
Terminated
Phase 3
A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer Start of enrollment: 2020 Dec 01
Active, not recruiting
Phase 2
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer Start of enrollment: 2022 Mar 07
Recruiting
Phase 3
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

1 citations
Reply to T. Shimoi et al and Y. Shimanuki et al.
Ingrid A. Mayer, Fengmin Zhao, Carlos L. Arteaga, William Fraser Symmans, Ben Ho Park
Journal of Clinical Oncology. 2021-09-23
9 citations
Preservation of quality of life in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer treated with tucatinib or placebo when adde...
Volkmar Mueller, Andrew M Wardley, Elisavet Paplomata, Erika Hamilton, Amelia Zelnak
European Journal of Cancer. 2021-06-29
15 citations
Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients.
Costanza Paoletti, Meredith M. Regan, Samuel M. Niman, Emily M. Dolce, Elizabeth P. Darga
NPJ Breast Cancer. 2021-06-11